Results 161 to 170 of about 111,189 (247)

Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study. [PDF]

BMC Nephrol
Lei W, Lai HP, Lv Y, Jin L, Xin J.
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis. [PDF]

Transl Cancer Res
Huang L, Chen K, Wang M, Guo C, Li Y, Yu Q, Liu Z, Li Z.   +7 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Severe hepatitis flares after antiviral withdrawal in chronic hepatitis B with lymphoma: Impact of rituximab. [PDF]

JHEP Rep
Liu YC, Shih YJ, Hsu CW, Jeng WJ, Chien RN.   +4 more
europepmc   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Adverse Prognostic Significance of Activation-Induced Cytidine Deaminase in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP. [PDF]

Cancer Rep (Hoboken)
Hardianti MS, Anggorowati N, Setiawan SA, Bagaskoro MR, Kurnianda J, Taroeno-Hariadi KW, Purwanto I, Hutajulu SH.   +7 more
europepmc   +1 more source

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual‐Center Study

The Journal of Dermatology, EarlyView.
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Ruggero Cascio Ingurgio, Angela Alfano, Aalia Syed, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Dedee F. Murrell   +6 more
wiley   +1 more source

Balancing Benefits and Risks of Rituximab in Pediatric Idiopathic Nephrotic Syndrome: The Critical Role of Age. [PDF]

Kidney Int Rep
Nakanishi K.
europepmc   +1 more source

AQP4+ NMOSD, MDA5+ Clinically Amyopathic Dermatomyositis and sHLH in a Pediatric Patient: A Case Report and Literature Review. [PDF]

J Inflamm Res
Zhang Z, Xiao Z, He F, Yin F, Peng J, Deng X.   +5 more
europepmc   +1 more source